Theragenics Corporation, a medical device company serving the prostate cancer treatment and surgical markets, today announced consolidated financial results for the fourth quarter and year ended December 31, 2005. Consolidated revenue for the quarter was $11.4 million, an increase of $2.9 million, or 34.3% over the fourth quarter of 2004. For the 12-month period, consolidated revenue was $44.3 million, an increase of $10.9 million or 32.8%, compared to the prior year. Net loss for the quarter was $236,000, or $0.01 per share, compared to a net loss of $1.3 million, or $0.04 per share in the fourth quarter of 2004.

Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20060118005148&newsLang=en)